Journal of Thrombosis and Thrombolysis

, Volume 30, Issue 3, pp 286–293

Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience

  • H. N. Abdel-Razeq
  • S. B. Hijjawi
  • S. G. Jallad
  • B. A. Ababneh


Cancer and its treatment are recognized risk factors for VTE. Compliance rate with published VTE prophylaxis guidelines is low. Decision on when to offer prophylaxis for hospitalized cancer patients is difficult to make. This paper describes current clinical practice in offering VTE prophylaxis to hospitalized cancer patients. Prophylaxis rate and rate of VTE will be correlated with the risk level. We prospectively followed all consecutive adult cancer patients admitted to medical units over a 5-month period. Caprini risk assessment model, with some modifications, was utilized to determine risk of VTE. Six hundred and six patients (51% males, median age 52 years, range 18–91) were included. Reasons for admission included infections (25%), chemotherapy (22%) and palliative care (10%). In addition to cancer, the most frequently encountered risk factors for VTE were: Immobilization (35%), age > 60 years (31%) and body mass index > 30 in (20%). Patients were grouped according to their total risk score: low (9%), moderate (44%) and high risk (47%). VTE prophylaxis rate was 55.1% for the whole study group. Following discharge, patients were followed for 60 days. The incidence of VTE was 3.4% in the moderate and 4.2% in the high risk groups, while none in the low risk group developed VTE. Many additional risk factors for VTE are usually encountered in hospitalized cancer patients. Cancer alone may not be an enough reason for VTE prophylaxis. Risk assessment model able to stratify patients into different risk categories will simplify decision making and enhance VTE prophylaxis rate.


Cancer Low molecular weight heparin Risk stratification Thromboembolism 


  1. 1.
    Kniffin WD, Baron JA, Barret J, Bikmeyer JD, Anderson FA (1994) The epidemiology of pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154:861–866CrossRefPubMedGoogle Scholar
  2. 2.
    Belch JJ, Lowe GDO, Ward AG, Forbes CD, Prentice CRM (1981) Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26:115–117PubMedGoogle Scholar
  3. 3.
    Heit JA, Silverstein MD, Mohr DN et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160:809–815CrossRefPubMedGoogle Scholar
  4. 4.
    Heit JA, O’Fallon WM, Petterson TM et al (2002) Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162:1245–1248CrossRefPubMedGoogle Scholar
  5. 5.
    Thodiyil PA, Kakkar AK (2002) Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 87:1076–1077PubMedGoogle Scholar
  6. 6.
    Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7PubMedGoogle Scholar
  7. 7.
    Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich J Jr, Hobbins TE et al (1992) The clinical course of pulmonary embolism. N Engl J Med 326:1240–1245CrossRefPubMedGoogle Scholar
  8. 8.
    Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Iliceto S, Prandoni P (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350:2257–2264CrossRefPubMedGoogle Scholar
  9. 9.
    Sørensen HT, Mellemkj’r L, Olsen JH et al (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–1850CrossRefPubMedGoogle Scholar
  10. 10.
    Caprini J, Arcelus J, Reyna J (2001) Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 38:12–19CrossRefPubMedGoogle Scholar
  11. 11.
    Kahn SR, Panju A, Geerts W, Pineo GF, Desjardins L, Turpie AG, Glezer S, Thabane L, Sebaldt RJ, CURVE Study Investigators (2007) Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 119:145–155CrossRefPubMedGoogle Scholar
  12. 12.
    Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, Huang W, Zayaruzny M, Emery L, Anderson FA Jr, ENDORSE Investigators (2008) Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371:387–394CrossRefPubMedGoogle Scholar
  13. 13.
    Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA Jr, IMPROVE Investigators (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism. Chest 132:936–945CrossRefPubMedGoogle Scholar
  14. 14.
    Ageno W, Squizzato A, Ambrosini F et al (2002) Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 87:746–750PubMedGoogle Scholar
  15. 15.
    Chopard P, Dorffler-Melly J, Hess U et al (2005) Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement. J Intern Med 257:352–357CrossRefPubMedGoogle Scholar
  16. 16.
    Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, Suarez C, Otero R, RIETE Investigators (2004) The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. J Thromb Haemost 2:1889–1891CrossRefGoogle Scholar
  17. 17.
    Motykie G, Zebala L, Caprini J, Lee C, Arcelus J, Reyna J, Cohen E, Courtney T, Sullivan L (2000) A guide to venous thromboembolism risk factor assessment. J Thromb Thrombolysis 9:253–262CrossRefPubMedGoogle Scholar
  18. 18.
    Sallah S, Wan JY, Nguyen NP (2002) Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87:575–579PubMedGoogle Scholar
  19. 19.
    Chew HK, Wun T, Harvey D et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458–464CrossRefPubMedGoogle Scholar
  20. 20.
    Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89:640–646CrossRefPubMedGoogle Scholar
  21. 21.
    Gerber DE, Grossman SA, Streiff MB (2006) Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 24:1310–1318CrossRefPubMedGoogle Scholar
  22. 22.
    Andtbacka RH, Babiera G, Singletary SE et al (2006) Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 243:96–101CrossRefPubMedGoogle Scholar
  23. 23.
    Chew HK, Wun T, Harvey DJ et al (2007) Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 25:70–76CrossRefPubMedGoogle Scholar
  24. 24.
    Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and risk of venous thrombosis. JAMA 293:715–722CrossRefPubMedGoogle Scholar
  25. 25.
    Haddad TF, Greeno EW (2006) Chemotherapy-induced thrombosis. Thromb Res 118:547–666CrossRefGoogle Scholar
  26. 26.
    Geerts W, Bergqvist D, Pineo G et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:381–453CrossRefGoogle Scholar
  27. 27.
    American Society of Clinical Oncology Guideline (2007) Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505CrossRefGoogle Scholar
  28. 28.
    NCCN, clinical practice guidelines in oncology (2008) Venous thromboembolic disease. J Natl Compr Canc Netw 6:716–753Google Scholar
  29. 29.
    Hull RD, Schellong SM, Tapson VF et al (2006) Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis 22:31–38CrossRefPubMedGoogle Scholar
  30. 30.
    Bosson JL, Pouchain D, Bergmann JF, for the ETAPE Study Group (2006) A prospective observational study of a cohort of outpatients with an acute medical event and reduced mobility: incidence of symptomatic thromboembolism and description of thromboprophylaxis practices. J Intern Med 260:168–176CrossRefPubMedGoogle Scholar
  31. 31.
    Khorana AA, Kuderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907CrossRefPubMedGoogle Scholar
  32. 32.
    Ay C, Simanek R, Vormittag R et al (2008) High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112:2703–2708CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • H. N. Abdel-Razeq
    • 1
  • S. B. Hijjawi
    • 1
  • S. G. Jallad
    • 1
  • B. A. Ababneh
    • 1
  1. 1.Division of Hematology and Medical Oncology, Department of Internal MedicineKing Hussein Cancer CenterAmmanJordan

Personalised recommendations